Jerome Durso compensation by year
INTERCEPT PHARMACEUTICALS Summary Compensation Table · all 3 fiscal years held| Component | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
| Salary | $599,524 | $690,750 | $714,813 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $2,057,016 | $5,474,865 | $2,547,438 |
| Option awards | $998,776 | $1,234,800 | $535,540 |
| Non-equity incentive | $231,737 | $435,994 | $634,552 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $21,910 | $33,945 | $23,120 |
| Total | $3,908,963 | $7,870,354 | $4,455,463 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: INTERCEPT PHARMACEUTICALS, INC. DEF 14A filed May 1, 2023, accession 0001104659-23-053540, and prior-year filings. Open the filing on EDGAR.
How this page was built: the INTERCEPT PHARMACEUTICALS, INC. filed document, accession 0001104659-23-053540. Every figure is read from that document and cited to the page and table it appears in. Filed May 1, 2023.
Equity holdings
unvested awards at FY2022 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 55,150 | $682,206 | — |
| PSU | 53,500 | $661,795 | — |
| RSU | 26,775 | $331,207 | — |
| RSU | 23,000 | $284,510 | — |
| PSU | 4,250 | $52,573 | — |
| RSU | 2,650 | $32,781 | — |
| Option | 4,350 | — | $99.66 |
| Option | 36,000 | — | $29.46 |
| Option | 45,675 | — | $14.44 |
Per the Outstanding Equity Awards at Fiscal Year-End table in INTERCEPT PHARMACEUTICALS, INC.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments INTERCEPT PHARMACEUTICALS discloses, by trigger · FY2022| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control, no termination | — | $1,999,301 | — | $1,999,301 |
| Disability | $501,900 | $2,183,924 | $0 | $2,685,824 |
| Death | $501,900 | $2,183,924 | $0 | $2,685,824 |
| Resignation for good reason, no change in control | $1,218,900 | $849,819 | $39,361 | $2,108,080 |
| Involuntary termination without cause | $1,218,900 | $849,819 | $39,361 | $2,108,080 |
| Change in control and involuntary termination | $2,437,800 | $1,999,301 | $78,721 | $4,515,822 |
Per the Potential Payments Upon Termination or Change in Control table in INTERCEPT PHARMACEUTICALS, INC.'s FY2022 proxy. Estimates as the company printed them; a dash means it printed no figure.
INTERCEPT PHARMACEUTICALS’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Jerome Durso · this page | President & CEO | $4,455,463 |
| Michelle Berrey | President of R&D and Chief Medical Officer | $1,614,245 |
| Andrew Saik | CFO | $1,387,699 |
| Linda Richardson | Chief Commercial Officer | $1,336,829 |
| Jared Freedberg | General Counsel | $1,311,653 |
Board service
INTERCEPT PHARMACEUTICALS board · FY2022How this board is paid
Company policy: INTERCEPT PHARMACEUTICALS pays directors a $50,000 cash retainer and $264,500 in RSUs/Options. As stated in INTERCEPT PHARMACEUTICALS's FY2022 proxy.
The full INTERCEPT PHARMACEUTICALS compensation record
free company briefThis page is one person within INTERCEPT PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the INTERCEPT PHARMACEUTICALS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are INTERCEPT PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.